These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Treatment of aluminium intoxication: a new scheme for desferrioxamine administration. Douthat WG; Acuña Aguerre G; Fernández Martín JL; Mouzo R; Cannata Andía JB Nephrol Dial Transplant; 1994; 9(10):1431-4. PubMed ID: 7816256 [TBL] [Abstract][Full Text] [Related]
3. Desferrioxamine-induced changes of aluminium kinetics during haemodialysis. Graf H; Stummvoll HK; Meisinger V Proc Eur Dial Transplant Assoc; 1981; 18():674-80. PubMed ID: 7329995 [TBL] [Abstract][Full Text] [Related]
4. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules. Barata JD; D'Haese PC; Pires C; Lamberts LV; Simões J; De Broe ME Nephrol Dial Transplant; 1996 Jan; 11(1):125-32. PubMed ID: 8649620 [TBL] [Abstract][Full Text] [Related]
5. Comparison of low-dose deferoxamine versus standard-dose deferoxamine for treatment of aluminium overload among haemodialysis patients. Kan WC; Chien CC; Wu CC; Su SB; Hwang JC; Wang HY Nephrol Dial Transplant; 2010 May; 25(5):1604-8. PubMed ID: 19948879 [TBL] [Abstract][Full Text] [Related]
6. Concomitant removal of aluminium and iron by haemodialysis and haemofiltration after desferrioxamine intravenous infusion. Ciancioni C; Poignet JL; Naret C; Delons S; Mauras Y; Allain P; Man NK Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():469-73. PubMed ID: 3991542 [TBL] [Abstract][Full Text] [Related]
7. Haemofiltration or haemodialysis in aluminium elimination? Sulkova S; Laurincova Z; Válek A Nephrol Dial Transplant; 1991; 6 Suppl 3():3-5. PubMed ID: 1775263 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of desferrioxamine and of its iron and aluminium chelates in patients on haemodialysis. Allain P; Chaleil D; Mauras Y; Beaudeau G; Varin MC; Poignet JL; Ciancioni C; Ang KS; Cam G; Simon P Clin Chim Acta; 1987 Dec; 170(2-3):331-8. PubMed ID: 3436066 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients. Verpooten GA; D'Haese PC; Boelaert JR; Becaus I; Lamberts LV; De Broe ME Nephrol Dial Transplant; 1992; 7(9):931-8. PubMed ID: 1328941 [TBL] [Abstract][Full Text] [Related]
10. Desferrioxamine induced aluminium removal in haemodialysis. Bonal J; Montoliu J; Löpez Pedret J; Bergadä E; Andrew L; Bachs M; Revert L Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():366-70. PubMed ID: 3991524 [TBL] [Abstract][Full Text] [Related]
11. Desferrioxamine in the treatment of aluminum overload. Ackrill P; Day JP Clin Nephrol; 1985; 24 Suppl 1():S94-7. PubMed ID: 3842106 [TBL] [Abstract][Full Text] [Related]
12. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity. McCarthy JT; Milliner DS; Johnson WJ Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295 [TBL] [Abstract][Full Text] [Related]
13. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload. D'Haese PC; Couttenye MM; Goodman WG; Lemoniatou E; Digenis P; Sotornik I; Fagalde A; Barsoum RS; Lamberts LV; De Broe ME Nephrol Dial Transplant; 1995 Oct; 10(10):1874-84. PubMed ID: 8592597 [TBL] [Abstract][Full Text] [Related]
14. Desferrioxamine treatment for aluminium and iron overload in uraemic patients by haemodialysis or haemofiltration. Baldamus CA; Schmidt H; Scheuermann EH; Werner E; Kaltwasser JP; Schoeppe W Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():382-6. PubMed ID: 3991527 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of low-dose desferrioxamine for the estimation of aluminium overload in haemodialysis patients. Janssen MJ; van Boven WP Pharm World Sci; 1996 Oct; 18(5):187-91. PubMed ID: 8933580 [TBL] [Abstract][Full Text] [Related]
16. Aluminium chelation therapy in dialysis patients: evidence for inhibition of haemoglobin synthesis by low levels of aluminium. Altmann P; Plowman D; Marsh F; Cunningham J Lancet; 1988 May; 1(8593):1012-5. PubMed ID: 2896867 [TBL] [Abstract][Full Text] [Related]
17. Newcastle bone disease in Hong Kong: a study of aluminum associated osteomalacia. Chan MK; Varghese Z; Li MK; Wong WS; Li CS Int J Artif Organs; 1990 Mar; 13(3):162-8. PubMed ID: 2189835 [TBL] [Abstract][Full Text] [Related]
18. Use of a desferrioxamine "microdose" to chelate aluminum in hemodialysis patients. Jorge C; Gil C; Possante M; Catarino MC; Cruz A; Andrade R; Teixeira R; Santos N; Ferreira A Clin Nephrol; 1999 Nov; 52(5):335-6. PubMed ID: 10585000 [No Abstract] [Full Text] [Related]
19. Use of ultrafiltration and chromatography to assess aluminum speciation in serum after deferoxamine administration. Canteros-Picotto A; Fernández-Martín JL; Cannata-Andía JB Am J Kidney Dis; 2000 Nov; 36(5):969-75. PubMed ID: 11054353 [TBL] [Abstract][Full Text] [Related]
20. Protein binding of aluminium in normal subjects and in patients with chronic renal failure. Rahman H; Channon SM; Skillen AW; Ward MK; Kerr DN Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():360-5. PubMed ID: 3991523 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]